KeyMed Biosciences Inc
KeyMed Biosciences Inc is a biotechnology and medical research company that develops and commercializes pharmaceutical products, primarily in the healthcare sector.
Business. KeyMed Biosciences Inc (2162.HK) is a biotechnology and medical research company operating within the healthcare sector. The firm is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not provided in the available data. Consequently, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.
Analyst recommendations
10 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
KeyMed Biosciences Inc (2162.HK) is a biotechnology and medical research company operating within the healthcare sector. The firm is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not provided in the available data. Consequently, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.
KeyMed Biosciences Inc has a market capitalization of 18.07 billion CNY, with a current market price of 60.5 CNY per share. The company's shares outstanding are 298.74 million, with no dilution observed between basic and diluted shares. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability and return metrics are not available in the valuation snapshot, and no industry-specific preferred metrics are provided in the industry configuration. As such, a direct comparison to cohort medians is not possible at this time.
The company's revenue concentration and geographic exposure are not disclosed in the available data. No segment-level revenue breakdown is provided, and there is no information on geographic distribution of sales.
The company's growth trajectory is not quantified in the available data. No revenue history or outlook for the current or next fiscal year is provided in the input data.
Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and no going-concern language in source documents. Dilution risk is currently low, with no near-term dilution pressure observed in the shares outstanding data.
Recent events, including filings and transcripts, are not disclosed in the available data. No specific events or disclosures are provided in the input data.
- KeyMed Biosciences Inc has a market capitalization of 18.07 billion CNY and a current market price of 60.5 CNY per share.
- The company's shares outstanding are 298.74 million, with no dilution observed between basic and diluted shares.
- Analysts have a strong positive outlook, with a mean price target of 87.67 CNY and a mean recommendation of 1.50 (strong buy).
- Liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
- No segment-level revenue breakdown or geographic exposure is disclosed in the available data.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥716.3M, +67,3% YoY; Operating income −3,8% YoY.
- ▍Revenue ¥716.3M, +67,3% YoY
- ▍Operating income −3,8% YoY
- ▍Net income −1,4% YoY
- ▍Free cash flow −19,6% YoY
- ▍Net margin -73.0%
Revenue ¥428.1M, +20,9% YoY; Operating income −45,1% YoY.
- ▍Revenue ¥428.1M, +20,9% YoY
- ▍Operating income −45,1% YoY
- ▍Net income −43,4% YoY
- ▍Free cash flow +5,2% YoY
- ▍Net margin -120.3%
Revenue ¥354.1M, +253,9% YoY; Operating income −17,1% YoY.
- ▍Revenue ¥354.1M, +253,9% YoY
- ▍Operating income −17,1% YoY
- ▍Net income −16,6% YoY
- ▍Free cash flow −22,7% YoY
- ▍Net margin -101.5%
Revenue ¥100.1M, −9,3% YoY; Operating income +92,6% YoY.
- ▍Revenue ¥100.1M, −9,3% YoY
- ▍Operating income +92,6% YoY
- ▍Net income +92,1% YoY
- ▍Free cash flow +86,5% YoY
- ▍Net margin -307.9%
Revenue ¥110.3M; Operating income -¥3.88B.
- ▍Revenue ¥110.3M
- ▍Operating income -¥3.88B
- ▍Net margin -3525.3%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 1,37 |
| Revenue | —no estimate | —no estimate | 2,0B CNY |
| Operating income | —no estimate | —no estimate | 213,1M CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- KeyMed Biosciences Inc Market data — financials · 2026-05-26
- KeyMed Biosciences Inc Market data — analyst estimates · 2026-05-26